• Where are the other Luxturna's? Challenges with gene therapy for inherited retinal diseases

• Reasoning about response rates

• The best ways to follow biopharma news and learn about the industry (in my opinion)

• Ergodicity and biotech, or why expected value is a mirage

• Developing a deeper understanding of diagnosis rates

• Unplanned success in drug development

• What is a good binding affinity for a drug?

• Pharmaceutical market sizes by countries and regions

• My book recommendations (updated annually)

• Pharmaceutical portfolio strategy implications of base rate probability of launch and revenue distributions

• Drug Vectors: identifying and plotting similar drugs through PubMed abstract text